***POSTPONED UNTIL FURTHER NOTICE***
March 9, 2020
March 3, 2020
The Connecticut Convergence Institute is proud to announce that two Pre-K Scholars have officially received K awards! Eliane Dutra of the 2018 cohort and Alicia Dugan of the 2014 cohort both received NIH Research Career Development Awards (K awards).
The Pre-K Scholar Career Development Award Program is a 2-year interactive program designed to equip junior faculty with the knowledge and competencies to effectively apply for an NIH Research Career Development Awards (K award) as well as become leaders in clinical and translational science. The long-term goal is to increase the pipeline of researchers applying for a K award and a culture that supports this goal.
Eliane received her D.D.S. from the Federal University of Santa Maria and her M.S.D. in Orthodontics from the Pontifical Catholic University of Parana, in Brazil. She then moved to the United States and obtained her Ph.D. and an Orthodontic Certificate from the Uconn Health. She is currently a full-time Assistant Professor in the Division of Orthodontics and the Program Director of the Orthodontic Predoctoral Curriculum. Eliane continues to devote her career to undergraduate and graduate education, as well as to research and patient care.
KO1 Project Abstract
Temporomandibular joint osteoarthritis (TMJ-OA) is a degenerative joint disease characterized by cartilage loss and sclerosis of the subchondral bone, causing pain and disability. There is an unmet clinical need to develop therapeutic interventions that are anabolic for the TMJ which could prevent or reverse degeneration of the TMJ cartilage. We have identified that the FDA approved treatment, intermittent parathyroid hormone (I-PTH), promotes anabolic responses in the osteochondral tissues of the TMJ. Our goal is to gain insights into the cellular and molecular mechanisms by which these effects are exerted. Our central hypothesis is that FGFR3 is the master regulator of the anabolic response observed in the TMJ due to I-PTH administration. This hypothesis will be tested by following specific aims: Specific Aim 1A: To determine the role of FGFR3 signaling in the anabolic effects of I-PTH administration in the MCC of the TMJ. We will delete FGFR3 in aSMA expressing cells in the mandibular condylar cartilage (MCC) and determine the effects of FGFR3 loss-of-function with and without I-PTH. We will also inject a soluble FGFR3 to rescue the FGFR3 conditional deleted to confirm that this signaling is the master regulator of the effects of I-PTH. Aim 1B: To define the molecular mechanism by which FGFR3 regulates the anabolic effects of I-PTH in vitro. FGFR3 in the primary chondrocytes from the MCC of triple collagen transgenic reporter mice will be inhibited using RNA silencing and specific FGFR3 inhibitor. Specific Aim 2: Evaluate the role Intermittent PTH plays in a model of cartilage injury and repair. The MCC of triple transgenic reporter mice will be injured and animals will receive either injected with I-PTH or saline to understand the role of I-PTH in early and delayed healing of the MCC.
Future Research Direction
To develop a deeper collaboration with multidisciplinary team in the UCONN School of Dental Medicine and School of Medicine, who are studying TMDs in generalized musculoskeletal disorder patients. To translate the basic research findings and strategies into clinical applications that can benefit patients with painful and disabling degenerative TMD disorders.
“The Pre-K Scholar Career Development Award Program has helped me to succeed in so many ways. From protecting my research time to guiding me in every single step of my KO1 application, the commitment of the program directors was invaluable in this whole challenging process. The interaction with other pre-K scholars has also helped to ease the struggles of grant application.”- Eliane Dutra
Alicia G. Dugan, PhD, is an industrial-organizational psychologist and assistant professor in the Division of Occupational and Environmental Medicine at the University of Connecticut’s School of Medicine. Dr. Dugan’s research focuses on worker well-being and work-life interface and the contextual factors that affect these experiences (i.e., self-care behavior, social support, resource availability). She uses community-based participatory research to develop interventions that improve worker well-being, and conducts dissemination and implementation research to understand factors that determine the successful translation of evidence-based health interventions into real world settings.
KO1 Project Abstract
The number of working-aged cancer survivors is 3.8 million and growing. Survivors are at risk for poor health and work outcomes, and are vulnerable to the competing demands of work and disease management (i.e., work-health conflict). Post-treatment job retention and other work-related outcomes have been only sparingly studied, falling between the fields of occupational medicine and cancer care. The available data suggest that about 40% of survivors do not successfully return to work, and that factors intrinsic to the workplace may explain this. The types and extent of formal and informal organizational support provided to cancer survivors at work are largely unknown. Moreover, existing return-to-work interventions are mainly designed for individuals (e.g., survivors) rather than administered at an organizational level. Our primary study goal is to determine how formal and informal organizational support at work influence health and work outcomes for survivors. A secondary goal is to assess whether and how cancer clinicians address return-to-work issues with patients. This study will investigate factors that promote or inhibit a successful return to work for breast and colorectal cancer survivors and may provide novel evidence that organizational support is an effective mechanism for enabling survivors to better manage their jobs and their health as they re-enter the workplace after primary treatment. It will translate disease management precepts from the Healthy Workplace Participatory Program, an evidence-based tool developed by investigators at our Center for the Promotion of Health in the New England Workplace (CPH-NEW). For Aim 1, we will investigate survivors’ return-to-work experiences of formal and informal organizational support, quality of life, cancer management behavior, and work-health conflict. Survey data will serve as a needs assessment for survivors and allow hypothesis testing. For Aim 2, we will convene a design team of survivors, clinicians, and managers to generate interventions using the Healthy Workplace Participatory Program step-by-step protocol which includes root causes analysis of RTW challenges, brainstorming and vetting of solutions, and plans for disseminating study outputs. For Aim 3, we will disseminate study outputs including an assessment tool and critical study findings.
Future Research Direction
Dr. Dugan’s plan is to initiate a new career trajectory that addresses the problems of workers with chronic disease, and her initial focus will be on patients returning to work after cancer treatment. She will redirect herself to a new line of independent research on the secondary prevention of work disability, building upon her existing strengths in worker health and well-being, self-care, and intervention design.
“I truly appreciate the support that I received from the CICATS Pre-K Scholar Career Development Award Program. It gave me the protected time and know-how to write a compelling grant application – one that I was proud to submit.”- Alicia Dugan
February 28, 2020
On Thursday, February 27th The Connecticut Convergence Institute combated the winter blues by hosting a Health Café on Seasonal Affective Disorder in conjunction with the YWCA Hartford Region. The event attracted over 35 attendees eager to learn more about the widespread disorder. While enjoying dinner, attendees engaged in the presentation of Glenn Konopaske, M.D. of UConn Health, as he touched upon the who, what, where, when, why, how to prevent and treatment options for Seasonal Affective Disorder. The session concluded with an interactive Q&A session.
On behalf of the CT Convergence Institute, we would like to thank everyone who came out to support, the YWCA Hartford Region and the Aetna Foundation for making this event possible.
February 26, 2020
On February 21st, Dr. Kevin Lo, Assistant Director of Education for the Connecticut Convergence Institute for Translation in Regenerative Engineering, visited the UConn Department of Mechanical Engineering in Storrs to discuss his regenerative engineering research as well as the educational programs of the CT Convergence Institute. Dr. Lo’s seminar discussed “Harnessing Small Signaling Molecules for Bone Regenerative Engineering: A Convergence Approach”.
Abstract- Clinicians and scientists working in the field of regenerative engineering are actively investigating a wide range of methods to promote musculoskeletal tissue regeneration. Small-molecule-mediated tissue regeneration is emerging as a promising strategy for regenerating various musculoskeletal tissues and several small molecule compounds have been recently discovered as potential signaling molecules for skeletal tissue repair and regeneration. However, a major challenge associated with utilizing these small molecules to regenerate a specific tissue/organ is the delivery of the therapeutic compounds directly to the target site to minimize potential systemic side effects. The presentation will focus on our recent work with small molecules that have the capacity to promote osteoblast differentiation and mineralization. Several proactive controlled delivery approaches have been developed in order to minimize off-target side effects of small molecules and will also be discussed.
February 20, 2020
Doctors at UConn Health have developed the first classification system for regenerative cell-based therapies designed to stratify therapies based on scientific evidence and potential for harm. Today, there are concerns regarding the clinical safety and efficacy of cell-based therapies throughout the scientific community and within public discourse. The unregulated U.S. stem cell market has been widely reported as it offers potentially harmful therapies to patients without FDA approval. Currently, there are no regenerative cell-based therapies approved by the FDA, although high demand for such treatments is ongoing.
In light of these concerns, the current climate has generated demand for a systematic method to assess potential therapies. Dr. Cato T. Laurencin, CEO of The Connecticut Convergence Institute for Translation in Regenerative Engineering at UConn Health, has created a new classification system for cell-based therapies. The objective was to create a strategy that will benefit patients, encourage regulatory efforts, and further inform the scientific community.
“The rapidly expanding direct-to-consumer marketplace allows for public consumption of unregulated treatments, so we identified an opportunity to enhance regulation and ensure greater public health,” says Laurencin.
The new system will aid in categorizing proposed interventions to determine suitability for immediate clinical use or therapies that require further investigational studies prior to clinical use. Utilization of this system will result in increased regulation and widespread standardization, which in turn decreases patient health and financial risks associated with unregulated treatments.
To learn more about the new classification system, view the newly published article here.
February 19, 2020
The Digital Health CT accelerator is a partnership among Hartford HealthCare, Trinity College, and UConn’s School of Business. The program provides startups the opportunity to work alongside health care providers, research institutions and investors to scale and accelerate their healthcare innovations. This MedTech Accelerator which is focused on Digital Health is designed to attract medical and healthcare technology companies to Hartford, and to expand economic development.
During an event on February 7th, ten healthcare startups presented their medical technology innovations that offer unique solutions for some of medicine’s greatest challenges. Among the presenters was Leila Daneshmandi, the co-founder of a cancer battling biotech company called Encapsulate, as well as a current Graduate Student of The Connecticut Convergence Institute for Translation in Regenerative Engineering. Encapsulate offers the ability to replicate a patient’s cancerous tissue outside of the body, allowing oncologists to pinpoint the most effective medications to combat them. The innovation has the potential to speed delivery of lifesaving treatments, spare patients from ineffective medication, and save money for insurance companies. The startup has been awarded the Technology in Space Prize by the International Space Station U.S. National Laboratory and Boeing.
On behalf of the CT Convergence Institute, we would like to congratulate Leila and the entire Encapsulate team. We are excited to see where this momentum will take them!
February 18, 2020
The Connecticut Convergence Institute is proud to announce that Liahna Gonda-King, of the REM program won the “Best Poster Presentation Award” at the Emerging Researchers National (ERN) Conference in STEM that took place in Washington D.C. last week. Liahna participated in the REM program of summer 2019 and is currently a high school teacher.
Liahna’s work entitled “Enhancing The Porosity of Sintered Microsphere Scaffold Systems in situ” focused on combining microsphere made from low and fast degrading polymers within the same construct as an approach to enhance the porosity of sintered microsphere scaffold systems in situ for more bone ingrowth. She shows that combining these microspheres could rapidly enhance the porosity of sintered microsphere scaffold systems while maintaining adequate mechanical properties and neutral pH levels.
The Research Experience and Mentoring (REM) program aims to mentor students from diverse backgrounds to prepare them for careers in STEM-related disciplines. The program recruits high school students, undergraduate students, and teachers in professional development to provide them with skills including communications, scientific writing, and collaboration, while providing a high quality research experience.
On February 13th, Dr. Laurencin provided the Henry Hill Lecture which took place at the joint meeting of the Northeast Region of National Organization for the Professional Advancement of Black Chemists and Chemical Engineers and Northeast Section of the American Chemical Society. The event was held at Pfizer in Cambridge, Massachusetts. The meeting featured a NESACES Board Meeting, followed by dinner and the presentations of the Henry A. Hill award and lecture. The Award for Outstanding Service went to James E. Phillips, while the lecture was facilitated by Dr. Cato T. Laurencin. The title of his presentation was “Regenerative Engineering: A Convergence Approach for Grand Challenges”.
Henry A. Hill Lecture- Dr. Henry Aaron Hill, the renowned chemist was a former Chairman of the American Chemical Society Northeast Section and the first African American President of the American Chemical Society. Dr. Hill’s outstanding contributions to chemistry, particularly industrial chemistry, and to the professional welfare of chemists are legendary. Dr. Hill’s first concern and interest was always in his fellow humans, and this was the driving force behind all that he did both in the chemical community and the world at large. In recognition of his many outstanding achievements NOBCChE identifies an outstanding Scientist or Engineer to be designated as the Henry A. Hill Distinguished Lecturer.
February 11, 2020
This past weekend Dr. Cato T. Laurencin received the 2019 UNESCO-Equatorial Guinea International Prize for Research in the Life Sciences, becoming the first American to earn this prestigious award. The ceremony took place during the Africa Union Heads of States Summit located in Addis Ababa, Ethiopia.
The Prize is awarded to a maximum of three laureates who have made significant efforts through scientific research towards improving the quality of human life. Dr. Laurencin was formally selected by the UNESCO Director-General for his fundamental contributions in the field of regenerative engineering, a field he has pioneered. He is known worldwide as a leader in biomaterials, nanotechnology, stem cell science, drug delivery systems, and regenerative engineering.
During Dr. Laurencin’s acceptance remarks, he stated “I am proud, humbled and invigorated to receive the only International Prize in Science given by the continent of Africa. As the first person from the African Diaspora to receive this award, I am re-dedicated to expanding the new field I have founded of Regenerative Engineering, creating new solutions for the world.”
At the University of Connecticut, Dr. Laurencin is the University Professor, the eighth to be designated by the school in its over 135 year history. He is Professor of Chemical and Biomolecular engineering, Materials Science and Engineering, and Biomedical Engineering; the Albert and Wilda Van Dusen Distinguished Endowed Professor of Orthopaedic Surgery; and Chief Executive Officer of the Connecticut Convergence Institute for Translation in Regenerative Engineering.
In 2016, Dr. Laurencin received the National Medal of Technology and Innovation, the highest honor bestowed in America for technological achievement, presented by the President of the United States. He received the Philip Hauge Abelson Prize from the American Association for the Advancement of Science “for signal contributions to the advancement of science in the United States.” In addition, he has also received the National Institutes of Health (NIH) Director’s Pioneer Award and the National Science Foundation (NSF) Emerging Frontiers in Research and Innovation Grant Award.
Dr. Laurencin is an elected member of the National Academy of Medicine, National Academy of Engineering, the American Academy of Arts and Sciences. He is the first person to win the oldest honors of both the National Academy of Engineering (the Simon Ramo Founders Award), and the National Academy of Medicine (the Walsh McDermott Medal). He is a fellow of the National Academy of Inventors and the American Association for the Advancement of Science. Internationally, he is an elected fellow of the African Academy of Sciences, the Indian National Academy of Sciences, the Indian National Academy of Engineering, and the World Academy of Sciences, as well as an Academician and elected member of the Chinese Academy of Engineering.
February 10, 2020
Dr. Kevin Lo and REM students attended the annual Emerging Researchers National (ERN) Conference in Science, Technology, Engineering and Mathematics (STEM) in Washington D.C. this past weekend. The conference is for undergraduate and graduate students who participate in programs funded by the NSF HRD Unit, including underrepresented minorities and persons with disabilities.
The objectives of the conference are to help undergraduate and graduate students to enhance their science communication skills and to better understand how to prepare for science careers in a global workforce. The 2-1/2 day conference includes student poster and oral presentations.
About the REM Students- The Research Experience and Mentoring (REM) program aims to mentor students from diverse backgrounds to prepare them for careers in STEM-related disciplines. The program recruits high school students, undergraduate students, and teachers in professional development to provide them with skills including communications, scientific writing, and collaboration, while providing a high quality research experience.
Each summer, participants in the REM program are welcomed at UConn Health for research training. Participants learn the basic aspects of research including research problem identification, experimental design, and execution. Our laboratories have researchers at all levels (post-docs, grad students, undergraduate and faculty members) so there is an opportunity to learn from a variety of scientists.